FCGR3A and neoplasm: While CD16-targeted BsAbs (e.g., AFM13) demonstrate enhanced safety and allogeneic potential for NK cell engagement, their therapeutic impact is limited by poor NK cell persistence within hostile tumor microenvironments (TMEs) (9, 10).